Long-acting drugs: people's expectations and physicians' preparedness. Are we readying to manage it? An Italian survey.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
21 Oct 2022
21 Oct 2022
Historique:
entrez:
25
10
2022
pubmed:
26
10
2022
medline:
27
10
2022
Statut:
ppublish
Résumé
To evaluate patients' expectations regarding long-acting antiretroviral agents and preferences about where to receive them. Multicenter cross-sectional survey-based study. Through an online survey, we asked people living with human immunodeficiency virus to judge their relationship with daily antiretroviral therapy (ART) and to give their opinion about long-acting drugs. We also collected data regarding the age of the patients, their site of follow-up, time since the diagnosis, and compliance to ART. Two hundred forty-two patients aged 18 to 79 years were included in the study: 58 (24%) females, 182 (75.2%) males, and 2 (0.8%) male-to-female transgenders. 81.8% of the said population had a good relationship with ART. 33.6% of them consider daily ART an obligation and a restriction to their freedom. One hundred forty-three (59.1%) patients already knew about long-acting drugs before our interview, and 215 (88.8%) patients were interested in it. One hundred fifty-six (64.4%) interviewees said they would still be interested in hospital-available injective long-acting drugs, although 57.9% of the patients would rather receive them at home. The data emerging from our survey reveal that around 90% of the people living with HIV are interested in changing their actual treatment with a long-acting one. Moreover, for the first time to our knowledge, such a high number of patients showed an enthusiastic response to the new opportunity to be treated directly at home. The introduction of these new drugs could be revolutionary and represents an important step toward treatment simplification.
Identifiants
pubmed: 36281167
doi: 10.1097/MD.0000000000030052
pii: 00005792-202210210-00090
pmc: PMC9592418
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30052Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
Gallo RC. A reflection on HIV/AIDS research after 25 years. Retrovirology. 2006;3:72.
European Centre for Disease Prevention and Control. HIV/AIDS surveillance in Europe. 2020. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/hiv-surveillance-report-2020.pdf . [access date 13 May, 2021].
Altice F, Evuarherhe O, Shina S, et al. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475–90.
Cambou MC, Landovitz RJ. Novel antiretroviral agents. Curr HIV/AIDS Rep. 2020;17:118–24.
Mulato A, Acosta R, Chang S, et al. Simulating HIV breakthrough and resistance development during variable adherence to antiretroviral treatment. J Acquir Immune Defic Syndr. 2021;86:369–77.
clinicaltrials.gov. ClinicalTrials.gov . Available at: https://clinicaltrials.gov/ct2/results?cond=HIV+Infections&term=long-acting&cntry=&state=&city=&dist= . [access date 13 May, 2021].
Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2020;396:1994–2005.
Kerrigan D, Murray M, Sanchez Karver T, et al. Feasibility of implementing long-acting injectable anti-retroviral therapy to treat HIV: a survey of health providers from the 13 countries participating in the ATLAS-2M trial. AIDS Res Hum Retroviruses. 2021;37:207–213
Koren DE, Fedkiv V, Zhao H, et al. Perceptions of long-acting injectable antiretroviral treatment regimens in a United States urban academic medical center. J Int Assoc Provid AIDS Care. 2020;19:2325958220981265.
Flexner C, Owen A, Siccardi M, et al. Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agents. 2020;57:106220.